Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Bought by First Trust Advisors LP

First Trust Advisors LP raised its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 2.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,240,932 shares of the company's stock after acquiring an additional 62,718 shares during the quarter. First Trust Advisors LP owned approximately 0.10% of Takeda Pharmaceutical worth $42,910,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of TAK. Blair William & Co. IL lifted its stake in shares of Takeda Pharmaceutical by 8.1% in the 4th quarter. Blair William & Co. IL now owns 12,199 shares of the company's stock valued at $162,000 after purchasing an additional 913 shares during the period. Sage Rhino Capital LLC raised its position in shares of Takeda Pharmaceutical by 14.9% in the fourth quarter. Sage Rhino Capital LLC now owns 11,840 shares of the company's stock worth $157,000 after acquiring an additional 1,538 shares during the period. Aaron Wealth Advisors LLC grew its position in shares of Takeda Pharmaceutical by 7.2% during the 4th quarter. Aaron Wealth Advisors LLC now owns 25,000 shares of the company's stock valued at $331,000 after acquiring an additional 1,670 shares during the period. OLD Mission Capital LLC raised its holdings in Takeda Pharmaceutical by 13.7% in the 4th quarter. OLD Mission Capital LLC now owns 13,977 shares of the company's stock worth $185,000 after purchasing an additional 1,687 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its position in Takeda Pharmaceutical by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 5,190 shares of the company's stock worth $69,000 after purchasing an additional 1,770 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Price Performance

TAK traded up $0.16 during midday trading on Monday, hitting $15.19. 1,100,897 shares of the company traded hands, compared to its average volume of 1,962,869. The business has a 50 day simple moving average of $14.72 and a two-hundred day simple moving average of $13.93. Takeda Pharmaceutical Company Limited has a 52-week low of $12.57 and a 52-week high of $15.37. The company has a market capitalization of $48.32 billion, a price-to-earnings ratio of 37.96, a PEG ratio of 0.24 and a beta of 0.39. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, equities analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.